Coya Therapeutics, Inc.
COYA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001835022
No open-market purchases or sales by Coya Therapeutics, Inc. insiders were filed in the last 90 days; 54 institutions reported holding it in 13F filings for Q2 2026, worth $45.5M in total; Greenlight Capital is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Coya Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Coya Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pavao Mark H | Director | – | Apr 9, 2026 | 1 |
| Snyder David S | Chief Financial Officer | 8,800 | Jan 26, 2026 | 1 |
| Berman Howard | Executive Chairman | – | Jan 26, 2026 | 1 |
| Grossman Fred | Chief Medical Officer | 2,710 | Jan 26, 2026 | 1 |
| Swaminathan Arun | Chief Executive Officer | 10,000 | Jan 26, 2026 | 1 |
| Ross Wilbur L Jr | Director | – | Jan 6, 2026 | 1 |
| Goldstein Dov A MD | Director | 27,557 | Jan 6, 2026 | 1 |
| Weinand Dieter | Director | – | Jan 6, 2026 | 1 |
| Villalobos Anabella | Director | 10,000 | Jan 6, 2026 | 1 |
| Lee Ann | Director | 17,479Indirect | Jan 6, 2026 | 1 |
| Garren Hideki | Director | 2,000 | Jan 19, 2024 | 0 |
| Hepner Adrian | Chief Medical Officer | 10,000 | Mar 1, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 (view filing) | Nov 14 | Same day | Snyder David SChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +1.80K | $7.19 | +$12.9K | +25.7%8.80K after | |
| Nov 13, 2024 (view filing) | Nov 13 | Same day | Swaminathan ArunChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | $7.36 | +$36.8K | +100.0%10.0K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Grossman FredChief Medical Officer | PPurchaseCommon Stock, par value $0.0001 per share | +2.71K | $7.37 | +$20.0K | New position2.71K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Swaminathan ArunChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | $7.34 | +$36.7K | New position5.00K after | |
| Mar 5, 2024 (view filing) | Aug 22, 2023 | 196 daysLate | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +1.00K | $3.62 | +$3.62K | +6.1%17.5K after | |
| Jan 4, 2023 (view filing)8:30 AM ET | Jan 3 | 1 day | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | |
| Jan 4, 2023 (view filing)8:30 AM ET | Jan 3 | 1 day | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –9.48K after | Derivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Hepner AdrianChief Medical Officer | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Hepner AdrianChief Medical Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –5.00K after | Derivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Snyder David SChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +7.00K | – | – | New position7.00K after | |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Snyder David SChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +3.50K | – | – | –3.50K after | Derivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Garren HidekiDirector | PPurchaseCommon Stock, par value $0.0001 per share | +2.00K | – | – | New position2.00K after | |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Garren HidekiDirector | PPurchaseCommon Stock, par value $0.0001 per share | +1.00K | – | – | –1.00K after | Derivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Villalobos AnabellaDirector | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Villalobos AnabellaDirector | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –5.00K after | Derivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Goldstein Dov A MDDirector | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Goldstein Dov A MDDirector | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –5.00K after | Derivative |